How to Interpret Your FibroScan (VCTE) Result

What Is a FibroScan and How Does VCTE Work?

FibroScan is the brand name for vibration-controlled transient elastography (VCTE), a non-invasive device that quantifies liver stiffness and fat without a needle biopsy. The probe sends a mild vibration pulse through the skin into the liver, then measures the speed of the resulting shear wave. Stiffer tissue transmits shear waves faster, yielding a higher kPa reading.

The technology was first validated in chronic hepatitis C cohorts in the early 2000s. A landmark meta-analysis by Tsochatzis et al. (2011) pooled 40 studies and over 7,000 patients, finding that VCTE had an area under the receiver operating characteristic curve (AUROC) of 0.84 for significant fibrosis (F2 or higher) and 0.94 for cirrhosis (F4) [1]. Since then, the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) have both incorporated VCTE into their clinical practice guidelines for non-invasive fibrosis assessment [2][3].

A single exam takes about 10 minutes. The technician places the probe in the right intercostal space while you lie supine with your right arm behind your head. The machine captures at least 10 valid measurements. Two outputs appear on your report: a liver stiffness measurement (LSM) in kPa and, if the machine uses the XL or M probe with CAP capability, a controlled attenuation parameter score in dB/m. Both numbers matter. The LSM tells your clinician how much fibrosis is present, while the CAP score estimates how much fat has accumulated in liver cells [4].

Understanding the kPa Scale: Fibrosis Stages F0 Through F4

Your FibroScan result is reported as a single number in kilopascals. That number maps to a fibrosis stage, but the exact cutoffs shift depending on the underlying liver disease. Cutoffs are not universal. A patient with hepatitis B and a patient with metabolic dysfunction-associated steatotic liver disease (MASLD) can have different thresholds for the same fibrosis stage, because inflammation and steatosis affect tissue stiffness independently of scarring.

For MASLD, which is the most common indication for FibroScan ordering in the United States, the AASLD 2023 practice guidance recommends the following interpretation thresholds [2]:

• Below 8.0 kPa: Low risk for advanced fibrosis. Annual monitoring may be sufficient.
• 8.0 to 12.0 kPa: Indeterminate zone. A second non-invasive test (such as the FIB-4 index or Enhanced Liver Fibrosis test) should be used to confirm or rule out advanced fibrosis.
• Above 12.0 kPa: High probability of advanced fibrosis (F3 or F4). Referral to hepatology and consideration of liver biopsy or treatment initiation is warranted.

For chronic hepatitis C, the Baveno VII consensus (2022) uses slightly different thresholds: below 10 kPa rules out clinically significant portal hypertension, while above 25 kPa rules it in [5]. These numbers illustrate why your clinician needs to know your specific diagnosis before interpreting the result.

A general-purpose staging chart used across multiple etiologies, derived from the Castera et al. (2005) validation study in hepatitis C (N=183), breaks down as follows [6]:

| Fibrosis Stage | kPa Range | Clinical Meaning | |---|---|---| | F0 | <7.0 | No fibrosis | | F1 | 7.0 to 8.9 | Mild fibrosis (portal) | | F2 | 9.0 to 9.5 | Significant fibrosis (periportal) | | F3 | 9.6 to 12.4 | Advanced fibrosis (bridging) | | F4 | 12.5 and above | Cirrhosis |

The numbers look precise, but they carry uncertainty. The AUROC for distinguishing F2 from F1 is lower (0.84) than for distinguishing F4 from non-F4 (0.94) [1]. Translation: FibroScan is excellent at detecting cirrhosis and quite good at ruling out significant fibrosis, but it sits in a gray zone for moderate stages. That is exactly why guidelines recommend combining VCTE with serum-based scores like FIB-4 when the result falls in the indeterminate range.

What Your CAP Score Tells You About Liver Fat

The controlled attenuation parameter (CAP) measures ultrasound signal attenuation caused by fat-laden hepatocytes. Fat absorbs ultrasound energy, so more fat means a higher CAP reading. The score ranges from 100 to 400 dB/m.

A 2017 individual-patient-data meta-analysis by Karlas et al. pooled 2,735 patients with biopsy-proven steatosis grading and established the following CAP thresholds [7]:

• S0 (below 5% steatosis): CAP below 238 dB/m
• S1 (5 to 33% steatosis): CAP 238 to 259 dB/m (AUROC 0.82)
• S2 (34 to 66% steatosis): CAP 260 to 290 dB/m (AUROC 0.86)
• S3 (above 66% steatosis): CAP above 290 dB/m (AUROC 0.88)

The CAP score has a wider confidence interval than the LSM, and it is influenced by body mass index. In patients with BMI above 30, the XL probe improves accuracy compared to the standard M probe [8]. If your report shows a CAP value above 280 dB/m alongside an LSM above 8.0 kPa, the combination strongly suggests metabolic steatohepatitis with at-risk fibrosis, which is the population studied in the MAESTRO-NASH trial (N=966) that led to the FDA approval of resmetirom (Rezdiffra) in March 2024 [9].

Your CAP score is not static. Weight loss of 7 to 10% body weight consistently reduces hepatic steatosis by at least one histologic grade. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean body weight reduction at 68 weeks [10]. While STEP-1 was a weight-management trial, the hepatology implications are direct: a patient who moves from 105 kg to 91 kg can expect meaningful CAP reduction within 6 to 12 months.

How to Know If Your FibroScan Result Is Reliable

Not every FibroScan exam produces trustworthy data. The machine itself reports quality metrics, and your clinician should check three criteria before acting on the numbers.

First, the IQR/median ratio must be below 0.30. The interquartile range (IQR) measures how much variability exists across the 10 individual measurements. If IQR/median exceeds 0.30, the result is unreliable and should be repeated [3]. Second, the success rate should exceed 60%. This means at least 6 of 10 attempted measurements yielded valid shear wave readings. Third, the median itself should be calculated from at least 10 valid shots.

Common causes of unreliable exams include narrow intercostal spaces, ascites (fluid between the probe and the liver), active hepatic inflammation (acute flares of hepatitis can transiently raise stiffness by 1 to 3 kPa), and recent food intake. Eating within 2 hours before a FibroScan can increase the LSM by up to 1.5 kPa due to postprandial hepatic blood flow changes [11]. This is why most centers require a 3-hour fast before the exam.

Obesity presents a specific challenge. In patients with BMI above 30, the standard M probe fails in up to 20% of examinations. The XL probe, which uses a lower ultrasound frequency and reaches deeper tissue, reduces failure rates to under 5% [8]. If your report notes "M probe, unreliable" and your BMI exceeds 30, ask for a repeat with the XL probe before concluding anything about your fibrosis stage.

What a High FibroScan Score Means for Your Health

A liver stiffness above 12.5 kPa signals a high probability of advanced fibrosis or cirrhosis. This is a clinical inflection point, not a death sentence. Fibrosis stage F3 and early F4 (compensated cirrhosis) are stages where aggressive intervention can halt progression and, in some cases, produce regression.

The clinical stakes at F3 and above include:

Screening obligations change. Once cirrhosis is confirmed, AASLD guidelines recommend ultrasound surveillance for hepatocellular carcinoma (HCC) every 6 months [2]. This is a hard recommendation, not optional.

Portal hypertension monitoring begins. The Baveno VII criteria use VCTE thresholds to risk-stratify patients: LSM above 20 to 25 kPa, combined with a platelet count below 150,000/μL, identifies patients likely to have clinically significant portal hypertension who may need upper endoscopy screening for varices [5].

Pharmacotherapy options open. For MASLD-related fibrosis at stage F2 or F3, resmetirom 80 mg or 100 mg daily is now FDA-approved based on the MAESTRO-NASH trial. At 52 weeks, 26% of patients on resmetirom 100 mg achieved fibrosis improvement by at least one stage with no worsening of steatohepatitis, compared to 14% on placebo (P<0.001) [9]. The drug specifically targets thyroid hormone receptor beta in hepatocytes to reduce lipotoxicity and fibrogenesis.

Lifestyle intervention is non-negotiable. A 2021 systematic review in Hepatology (Vilar-Gomez et al.) found that patients who achieved 10% or greater weight loss had a 45% rate of fibrosis regression, including regression from F3 to F2 or F1 [12]. The mechanism involves reduced hepatic de novo lipogenesis, decreased stellate cell activation, and resolution of lobular inflammation.

What a Low or Normal FibroScan Score Means

A result below 7.0 kPa with a CAP under 238 dB/m is reassuring. It means no detectable fibrosis and no significant steatosis. For patients with known risk factors for liver disease (obesity, type 2 diabetes, alcohol use above 2 drinks per day), a normal FibroScan does not mean permanent clearance. Repeat testing every 2 to 3 years is reasonable if metabolic risk factors persist.

A low LSM but elevated CAP deserves attention. This combination (for example, 5.5 kPa with CAP 310 dB/m) means you have significant liver fat but no scarring yet. This is the window where intervention is most effective and the prognosis is best. The AASLD 2023 guidance identifies this population as "at-risk MASLD" when accompanied by a FIB-4 score below 1.3, recommending lifestyle modification and metabolic risk factor optimization rather than pharmacotherapy [2].

The American Diabetes Association (ADA) 2024 Standards of Care recommend FIB-4 screening for all patients with type 2 diabetes, with VCTE as the next step when FIB-4 falls between 1.3 and 2.67 [13]. This two-step pathway catches patients who have progressed beyond steatosis into early fibrosis.

How to Lower Your FibroScan Score

Liver stiffness is not a fixed trait. Fibrosis, particularly at stages F1 and F2, can regress with sustained intervention. The three evidence-based approaches, ranked by effect size, are weight loss, pharmacotherapy, and alcohol cessation.

Weight loss remains the single most effective intervention. The threshold for histologic improvement is 7% body weight loss for steatohepatitis resolution and 10% for fibrosis regression [12]. In practice, this means a 100 kg patient needs to lose and maintain a loss of 7 to 10 kg. GLP-1 receptor agonists and dual GIP/GLP-1 agonists produce this magnitude of loss reliably. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean weight loss at 72 weeks [14]. No dietary intervention in clinical trials has matched these pharmacological results.

Resmetirom is the first drug approved specifically for MASLD-related fibrosis. It works through a distinct mechanism (thyroid hormone receptor beta agonism) and can be combined with GLP-1 agonists, though combination data are still emerging.

Alcohol reduction produces rapid improvement. In alcohol-associated liver disease, abstinence can reduce liver stiffness by 3 to 5 kPa within 6 months, reflecting resolution of alcoholic steatohepatitis and early fibrosis [15].

A repeat FibroScan is typically performed 12 months after intervention onset. A drop of 20% or more in kPa is considered clinically meaningful, though the exact minimal important difference is still debated in the literature.

FibroScan vs. Other Non-Invasive Fibrosis Tests

VCTE is not the only non-invasive fibrosis assessment available. Understanding where it fits among alternatives helps you and your clinician choose the right tool.

FIB-4 index uses age, ALT, AST, and platelet count. It costs nothing beyond routine labs and serves as the recommended first-line screening test per AASLD and ADA guidelines [2][13]. FIB-4 below 1.3 rules out advanced fibrosis with a negative predictive value above 90%. FIB-4 above 2.67 rules it in. The indeterminate zone (1.3 to 2.67) is where VCTE adds the most value.

Magnetic resonance elastography (MRE) is more accurate than VCTE for intermediate fibrosis stages, with an AUROC of 0.92 for F2 or higher compared to VCTE's 0.84 [16]. MRE also performs better in obese patients and samples a larger liver volume. The tradeoffs: MRE costs 5 to 10 times more, requires MRI scanner access, and takes 30 to 45 minutes.

Enhanced Liver Fibrosis (ELF) test is a blood panel measuring hyaluronic acid, TIMP-1, and PIIINP. The NICE guidelines in the United Kingdom recommend ELF as a second-line test alongside VCTE [17]. An ELF score below 9.8 rules out advanced fibrosis; above 11.3 rules it in.

The practical pathway for most patients: FIB-4 first, VCTE second if FIB-4 is indeterminate, MRE or liver biopsy if both remain inconclusive or if treatment decisions require histologic confirmation.

When to Repeat Your FibroScan

The frequency of repeat testing depends on your baseline result and what has changed since the last exam.

Baseline below 8.0 kPa and low metabolic risk: Repeat in 3 to 5 years, or sooner if new risk factors emerge (weight gain above 10%, new diabetes diagnosis, heavy alcohol use).

Baseline 8.0 to 12.0 kPa (indeterminate zone): Repeat in 12 months, ideally after implementing lifestyle or pharmacologic intervention. Pair with FIB-4 or ELF to improve classification certainty.

Baseline above 12.0 kPa (advanced fibrosis/cirrhosis): Annual monitoring is standard. If on resmetirom or another antifibrotic, repeat at 12 months to assess treatment response. AASLD recommends continuing HCC surveillance with abdominal ultrasound every 6 months regardless of VCTE trajectory [2].

Post-intervention reassessment: After bariatric surgery, expect LSM reduction within 12 to 24 months. A prospective French cohort (N=381) showed mean LSM dropped from 8.9 kPa to 5.6 kPa at 5 years post-sleeve gastrectomy, with 85% of patients achieving F0 on biopsy [18].

Always fast for at least 3 hours before a repeat exam and schedule the test at a similar time of day to minimize physiologic variability.